Covaxin 65.2 per cent effective against Delta varient, says Bharat Biotech

Bharat Biotechs Covaxin has demonstrated 778 per cent effectiveness against symptomatic Covid19 and 652 per cent protection against the new Delta variantThe company on Saturday said it concluded the final analysis of Covaxin efficacy from Phase 3 trialsThe efficacy analysis demonstrates Covaxin to be 934 per cent effective against severe symptomatic Covid19 cases while safety analysis shows adverse events reported were similar to placebo with 12 per cent of subjects experiencing commonly known side effects and less than 05 per cent feeling serious adverse eventsThe efficacy data demonstrates 636 per cent protection against asymptomatic Covid19 a release from the citybasedvaccine maker saidPhase 3 clinical trials of the vaccine was an eventdriven analysis of 130 symptomatic Covid19 cases reported at least two weeks after the second dose conducted at 25 sites across IndiaThe whole virion inactivated vaccine against SARSCoV2 was developed in partnership with Indian Council of Medical Research and National Institute of Virology in Pune Krishna Ella Chairman and Managing Director of Bharat Biotech said The successful safety and efficacy readouts of Covaxin as a result of conducting the largest ever Covid19 vaccines trials in India establishes the ability of India and developing world countries to focus towards innovation and novel product developmentWe are proud to state that Innovation from India will now be available to protect global populationsDirector General of ICMR Balram Bhargava said I am delighted to note that Covaxin developed by ICMR and BBIL under an effective public private partnership has demonstrated an overall efficacy of 778 per cent in Indias largest Covid19 phase 3 clinical trial thus farAlso read Brazil suspends Covaxin deal orders probeOur scientists at ICMR and BBIL have worked tirelessly to deliver a truly effective vaccine of highest international standardsHe further said Covaxin will not only benefit the Indian citizens but would also immensely contribute to protect the global community against the deadly SARSCoV2 virusI am also pleased to see that Covaxin works well against all variant strains of SARSCoV2The successful development of Covaxin has consolidated the position of Indian academia and Industry in the global arena Bhargava saidThe Phase 3 trials were conducted between November 16 2020 and January 7 2021 with 25798 participants who were randomised to BBV152 or placebo groupsThe preprint data of COVAXIN efficacy has not been certified by peerreview according to Medrxiv in which the data was publishedThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever